SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

Data Sheet (Cat.No.T1418)

TargetMol

Bucladesine sodium

Chemical Properties



CAS No. : 16980-89-5

Formula: C18H23N5NaO8P

Molecular Weight: 491.37

Appearance: no data available

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Biological Description

Description	Bucladesine sodium (DC2797) is a cAMP analog with cell-permeable properties. Bucladesine sodium is also a cAMP-dependent protein kinase (PKA) activator and a phosphodiester (PDE) inhibitor. Bucladesine sodium has anti-inflammatory activity.
Targets(IC50)	PKA,PDE
In vitro	**METHODS**: Human eosinophil EoL-1 cells were treated with Bucladesine sodium (10-100 μM) for 8 days and activity was measured using PKA assay. **RESULTS**: Proliferation of EoL-1 cells treated with Bucladesine sodium increased in a time-dependent manner. [1] **METHODS**: PC12 cells were treated with Bucladesine sodium (1 mM) for 72 h. TNF-α levels were measured by ELISA assay. **RESULTS**: Bucladesine sodium increased the activity of PKA. [2]
In vivo	**METHODS**: To study the anti-inflammatory activity in vivo, Bucladesine sodium (0.24-0.7 μg/kg) was administered intraperitoneally to a mouse model of copper pine demyelination once daily for seven days. **RESULTS**: Bucladesine had a protective effect on myelin formation. Enhanced intracellular cAMP prevented demyelination and exerted anti-inflammatory and anti-apoptotic properties in a mouse model of copper pine demyelination. [3] **METHODS**: To investigate the effects on liver injury, Bucladesine sodium (0.5-500 mg/kg) was intraperitoneally injected into C57BL/6J jcl mice, and liver injury was induced by the intravenous injection of rTNF-α (1.0 μg/kg) and intraperitoneal injection of D-gal (500 mg/kg) after 1 h. The **RESULTS** showed that Bucladesine protected against hepatic injury in C57BL/6J jcl mice. **RESULTS**: Bucladesine protected mice from TNF-α/D-gal-induced liver injury. Bucladesine significantly enhanced the expression of Hsp70 in hepatocytes of D-gal/TNFα-injected mice, which was closely related to the inhibition of liver injury. [4]
Animal Research	Animal: Mice. Formulation: water/DMSO (9:1). Dosages: 600 nM. Administration: i.p.

Solubility Information

Solubility	H2O: 49.1 mg/mL (100 mM), DMSO: 55 mg/mL (111.93 mM), (< 1 mg/ml refers to the product slightly soluble or insoluble)

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.0351 mL	10.1756 mL	20.3513 mL
5 mM	0.407 mL	2.0351 mL	4.0703 mL
10 mM	0.2035 mL	1.0176 mL	2.0351 mL
50 mM	0.0407 mL	0.2035 mL	0.407 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Jung Y. Comparative Analysis of Dibutyric cAMP and Butyric Acid on the Differentiation of Human Eosinophilic Leukemia EoL-1 Cells. Immune Netw. 2015 Dec;15(6):313-8.